Illumina Analyst Price Targets - Benzinga

SPY774.49 QQQ754.04 BTC/USD83,043.37−0.28%DIA507.14 GLD377.87+0.53%TLT76.65−0.64%

Illumina Inc

ILMNNASDAQ

Trade with Public

Trade with Public

$267.76

-5.78-2.11%

Last update: Oct 7, 4:48 PM

$267.81

-5.73-2.1%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Illumina Analyst Price Targets - Benzinga

Illumina Analyst Price Targets

Wall Street analyst price targets and consensus rating for Illumina (ILMN).

Price Target Range — 9 Quarters

Analyst Consensus — 18 Analysts

11Buy

5Hold

2Sell

Consensus RatingBuy# Analysts18Avg. Consensus PT$185Upside to Avg. PT-30.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Underweight	$160→$200
Oct 5, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$230→$310
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$226→$305
Sep 29, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$220→$300
Sep 28, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$225→$305
Sep 9, 2026	UBS	Doug Schenkel	Upgrade	Neutral→Buy	$135→$260
Sep 3, 2026	Argus Research	Jasper Hellweg	PT Raise	Buy	$180→$235
Aug 3, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$190→$205
Aug 3, 2026	Citigroup	Joanne Wuensch	PT Raise	Sell	$95→$113
Aug 3, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$200→$225
Jul 31, 2026	RBC Capital	Dan Leonard	PT Raise	Outperform	$170→$230
Jul 31, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$220→$230
Jul 31, 2026	TD Cowen	Dan Brennan	PT Raise	Hold	$192→$210
Jul 31, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$200→$226
Jul 31, 2026	Stifel	Daniel Arias	PT Raise	Buy	$155→$225
Jul 31, 2026	Barclays	Luke Sergott	PT Raise	Underweight	$145→$160
Jul 17, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$175→$210
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$140→$190
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$155→$200
Jul 1, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$170→$200

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Underweight on Illumina, Raises Price Target to $200

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the price target from $160 to $200.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Illumina, Raises Price Target to $310

RBC Capital analyst Dan Leonard maintains Illumina (NASDAQ:ILMN) with a Outperform and raises the price target from $230 to $310.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Illumina, Raises Price Target to $305

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $226 to $305.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Illumina, Raises Price Target to $300

Leerink Partners analyst Puneet Souda maintains Illumina (NASDAQ:ILMN) with a Outperform and raises the price target from $220 to $300.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Illumina, Raises Price Target to $305

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:ILMN) with a Overweight and raises the price target from $225 to $305.

Benzinga Newsdesk

Grail Analyst Sees Massive Market Potential with Valuation Headwinds

Grail "is a pure play," according to RBC Capital Markets. The company offers a tool for screening malignancies that lack standard protocols.

Vandana Singh